Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia

Michael J. Keating; Hagop Kantarjian; Susan O'Brien; Charles Koller; Moshe Talpaz; Jay Schachner; Craig C. Childs; Emil J. Freireich; Kenneth B. McCredie

Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia

Michael J. Keating, Hagop Kantarjian, Susan O'Brien, Charles Koller, Moshe Talpaz, Jay Schachner, Craig C. Childs, Emil J. Freireich, Kenneth B. McCredie

Leukemia

Research output: Contribution to journal › Article › peer-review

230 Scopus citations

Abstract

Thirty-three patients with chronic lymphocytic leukemia (CLL) with advanced Rai stage (III-IV) or progressive Rai stage (0-11) disease were treated with fludarabine as a single agent. Eleven patients (33%) obtained a complete remission (CR), 13 (39%) a clinical CR with residual nodules as the only evidence of disease (nodular partial remission [PR]), and two patients (6%) achieved a PR for a total response rate of 79%. Response was rapid, usually occurring after three to six courses of treatment. The major morbidity was infection. Febrile episodes occurred in 13% of the courses (pneumonia 6%, minor infection 4%, and transient fever of undocumented cause 3%). Fludarabine appears to be the most cytoreductive single agent so far studied in CLL.

Original language	English (US)
Pages (from-to)	44-49
Number of pages	6
Journal	Journal of Clinical Oncology
Volume	9
Issue number	1
State	Published - 1991

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

@article{caebbbf4d90c489e90718d5c76209f5d,

title = "Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia",

abstract = "Thirty-three patients with chronic lymphocytic leukemia (CLL) with advanced Rai stage (III-IV) or progressive Rai stage (0-11) disease were treated with fludarabine as a single agent. Eleven patients (33%) obtained a complete remission (CR), 13 (39%) a clinical CR with residual nodules as the only evidence of disease (nodular partial remission [PR]), and two patients (6%) achieved a PR for a total response rate of 79%. Response was rapid, usually occurring after three to six courses of treatment. The major morbidity was infection. Febrile episodes occurred in 13% of the courses (pneumonia 6%, minor infection 4%, and transient fever of undocumented cause 3%). Fludarabine appears to be the most cytoreductive single agent so far studied in CLL.",

author = "Keating, {Michael J.} and Hagop Kantarjian and Susan O'Brien and Charles Koller and Moshe Talpaz and Jay Schachner and Childs, {Craig C.} and Freireich, {Emil J.} and McCredie, {Kenneth B.}",

year = "1991",

language = "English (US)",

volume = "9",

pages = "44--49",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "1",

}

TY - JOUR

T1 - Fludarabine

T2 - A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia

AU - Keating, Michael J.

AU - Kantarjian, Hagop

AU - O'Brien, Susan

AU - Koller, Charles

AU - Talpaz, Moshe

AU - Schachner, Jay

AU - Childs, Craig C.

AU - Freireich, Emil J.

AU - McCredie, Kenneth B.

PY - 1991

Y1 - 1991

N2 - Thirty-three patients with chronic lymphocytic leukemia (CLL) with advanced Rai stage (III-IV) or progressive Rai stage (0-11) disease were treated with fludarabine as a single agent. Eleven patients (33%) obtained a complete remission (CR), 13 (39%) a clinical CR with residual nodules as the only evidence of disease (nodular partial remission [PR]), and two patients (6%) achieved a PR for a total response rate of 79%. Response was rapid, usually occurring after three to six courses of treatment. The major morbidity was infection. Febrile episodes occurred in 13% of the courses (pneumonia 6%, minor infection 4%, and transient fever of undocumented cause 3%). Fludarabine appears to be the most cytoreductive single agent so far studied in CLL.

AB - Thirty-three patients with chronic lymphocytic leukemia (CLL) with advanced Rai stage (III-IV) or progressive Rai stage (0-11) disease were treated with fludarabine as a single agent. Eleven patients (33%) obtained a complete remission (CR), 13 (39%) a clinical CR with residual nodules as the only evidence of disease (nodular partial remission [PR]), and two patients (6%) achieved a PR for a total response rate of 79%. Response was rapid, usually occurring after three to six courses of treatment. The major morbidity was infection. Febrile episodes occurred in 13% of the courses (pneumonia 6%, minor infection 4%, and transient fever of undocumented cause 3%). Fludarabine appears to be the most cytoreductive single agent so far studied in CLL.

UR - http://www.scopus.com/inward/record.url?scp=0026015638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026015638&partnerID=8YFLogxK

M3 - Article

C2 - 1702145

AN - SCOPUS:0026015638

SN - 0732-183X

VL - 9

SP - 44

EP - 49

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 1

ER -

Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this